About The Maynard Lab
The Maynard Lab develops protein therapeutics to address unmet medical needs in infectious diseases. These proteins aim to directly interfere in disease progression or augment essential immune system activities. This work involves design of proteins with therapeutic potential, production in recombinant expression systems, biophysical and biochemical analyses to elucidate the molecular basis of activity and, ultimately, in vitro and in vivo experiments to evaluate a protein's therapeutic potential.
Maynard Lab researchers look at the following:
- Advanced antibody therapeutics: Discovery and design of antibodies endowed with novel capabilities, such as antibodies with conditional activity at the site of disease and antibodies that resist pathogen efforts to evade capture.
- Vaccines that outsmart pathogens: Using what we learn from antibodies that prevent disease, especially antibodies that protect despite a pathogen's efforts to evade the immune system, we aim to design vaccine antigens that induce potently protective antibody responses.
- T cell-based therapeutics: Redirect cellular immune responses towards virally-infected cells through manipulation of T cell receptor-peptide MHC interactions.
2023 Research
-
Maynard JA, Segatori L. Editorial overview: Tissue, cell, and pathway engineering: Recent innovations in biomedical technologies. Curr Opin Biotechnol. 2023 Aug 15;83:102981. Epub ahead of print. PMID: 37591033.
-
Osickova A, Knoblochova S, Bumba L, Man P, Kalaninova Z, Lepesheva A, Jurnecka D, Cizkova M, Biedermannova L, Goldsmith JA, Maynard JA, McLellan JS, Osicka R, Sebo P, Masin J. A conserved tryptophan in the acylated segment of RTX toxins controls their β2 integrin-independent cell penetration. J Biol Chem. 2023 Jun 28;299(8):104978. Epub ahead of print. PMID: 37390987; PMCID: PMC10392135.
-
Yount KS, Hall JM, Caution K, Shamseldin MM, Guo M, Marion K, Fullen AR, Huang Y, Maynard JA, Quataert SA, Deora R, Dubey P. Systemic priming and intranasal booster with a BcfA-adjuvanted acellular pertussis vaccine generates CD4+ IL-17+ nasal .... Front Immunol. 2023 May 18;14:1181876. PMID: 37275891; PMCID: PMC10232778.
-
Silva RP, Huang Y, Nguyen AW, Hsieh CL, Olaluwoye OS, Kaoud TS, Wilen RE, Qerqez AN, Park JG, Khalil AM, Azouz LR, Le KC, Bohanon AL, DiVenere AM, Liu Y, Lee AG, Amengor DA, Shoemaker SR, Costello SM, Padlan EA, Marqusee S, Martinez- Sobrido L, Dalby KN, D'Arcy S, McLellan JS, Maynard JA. Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses. Elife. 2023 Mar 21;12:e83710. PMID: 36942851; PMCID: PMC10030117.
-
Qerqez AN, Silva RP, Maynard JA. Outsmarting Pathogens with Antibody Engineering. Annu Rev Chem Biomol Eng. 2023 Mar 14. Epub ahead of print. PMID: 36917814.
2022 Research
-
Bowen JE, Park YJ, Stewart C, Brown JT, Sharkey WK, Walls AC, Joshi A, Sprouse KR, McCallum M, Tortorici MA, Franko NM, Logue JK, Mazzitelli IG, Nguyen AW, Silva RP, Huang Y, Low JS, Jerak J, Tiles SW, Ahmed K, Shariq A, Dan JM, Zhang Z, Weiskopf D, Sette A, Snell G, Posavad CM, Iqbal NT, Geffner J, Bandera A, Gori A, Sallusto F, Maynard JA, Crotty S, Van Voorhis WC, Simmerling C, Grifantini R, Chu HY, Corti D, Veesler D. SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. Sci Immunol. 2022 Nov 10:eadf1421. Epub ahead of print. PMID: 36356052.
-
Liu Y, Nguyen AW, Maynard JA. Engineering antibodies for conditional activity in the solid tumor microenvironment. Curr Opin Biotechnol. 2022 Sep 28;78:102809. Epub ahead of print. PMID: 36182870.
-
Goldsmith JA, DiVenere AM, Maynard JA, McLellan JS. Structural basis for non- canonical integrin engagement by Bordetella adenylate cyclase toxin. Cell Rep. 2022 Aug 16;40(7):111196. PMID: 35977491; PMCID: PMC9416875.
-
DiVenere AM, Amengor D, Silva RP, Goldsmith JA, McLellan JS, Maynard JA. Blockade of the Adenylate Cyclase Toxin Synergizes with Opsonizing Antibodies to Protect Mice against Bordetella pertussis. mBio. 2022 Aug 30;13(4):e0152722. Epub 2022 Aug 3. PMID: 35920558; PMCID: PMC9426472.
-
Y Liu, AG Lee, AW Nguyen and JA Maynard. An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH. Journal of Biological Chemistry 298 (4). April 1, 2022.
-
Y Ha, X Wang, HM Liljestrand, JA Maynard and LE Katz. Elucidating the mechanism of cellular uptake of fullerene nanoparticles. Environmental Engineering Research 27 (2), 173-182. April 2022.
-
SM Costello, SR Shoemaker, HT Hobbs, AW Nguyen, CL Hsieh, JA Maynard, JS McLellan, JE Pak and S Marqusee. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. Nature Structural & Molecular Biology 29 (3), 229-238. March 2, 2022
-
RP Silva, AM DiVenere, D Amengor and JA Maynard. Antibodies binding diverse pertactin epitopes protect mice from Bordetella pertussis infection. Journal of Biological Chemistry 298 (3). March 1, 2022.
2021 Research
-
AC* Patterson-Orazem, AN* Qerqez, LR* Azouz, M* Thu Ma, SE Hill, Y Ku, LA Schildmeyer, JA Maynard and RL Lieberman. Recombinant antibodies recognize conformation-dependent epitopes of the leucine zipper of misfolding-prone myocilin. JBC 297(3): 101067. September 2021.
-
J Goldsmith, AM DiVenere, JA Maynard and JS McLellan. Structural basis for antibody binding to adenylate cyclase toxin reveals RTX-linkers as key neutralization-sensitive epitopes. Plos Pathogens 17(9): e1009920. September 21, 2021.
-
JM Schaub, C-W Chou, H-C Kuo, K Javanmardi, C-L Hsieh, JA Goldsmith, AM DiVenere, KC Le, D Wrapp, PO Byrne, CK Hjorth, NV Johnson, J Ludes-Meyers, AW Nguyen, N Wang, JJ Lavinder, GC Ippolito, JA Maynard, JS McLellan and IJ Finkelstein. Expression and characterization of SARS-CoV-2 spike protein. Nature Protocols. October 5, 2021.
-
Y* Huang, AW* Nguyen, C-L Hsieh, R Silva, OS Olaluwoye, RE Wilen, TS Kaoud, LR Azouz, AN Qerqez, KC Le, AL Bohanon, AM DiVenere, Y Liu, AG Lee, D Amengor, KN Dalby, S D’Arcy, JS* McLellan and JA* Maynard. Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses. August 20, 2021.
-
AW Nguyen and JA Maynard. Engineering antibody-based therapeutics: progress and opportunities. Invited review in Protein Engineering: Tools and Applications, edited by Huimin Zhao, Sang Yup Lee, Jens Nielsen, Gregory Stephanopoulos, August 6, 2021.
-
S-F Yuan, SM Brooks, AW Nguyen, W-L Lin, TG Johnston, JA Maynard, A Nelson and HS Alper. Bioproduced Proteins On Demand (Bio-POD) in hydrogels using Pichia pastoris. Bioactive Materials, 6(8): 2390-2399. August 2021.
-
SM Costello, SR Shoemaker, HT Hobbs, AW Nguyen, C-L Hsieh, JA Maynard, JS McLellan, JE Pak and S Marqusee. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. Submitted. bioRxiv 2021.07.11.451855. July 11, 2021.
-
Y-J Ha, ZX Wang, LE Katz, JA Maynard and HM Liljestrand. Elucidating the mechanism of cellular uptake of fullerene nanoparticle. Environmental Engineering Research, 27(2): 200658. March 3, 2021.
2020 Research
-
C-L Hsieh, JA Goldsmith, JM Schaub, AM DiVenere, H-C Kuo, K Javanmardi, KC Le, D Wrapp, AG Lee, Y Liu, C-W Chou, PO Byrne, CK Hjorth, NV Johnson, J Ludes-Meyers, AW Nguyen, J Park, N Wang, D Amengor, JA* Maynard, IJ* Finkelstein and JS McLellan. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science, eabd0826. July 23, 2020.
-
H Tanno, J McDaniel, C Stevens, W Voss, J Li, R Durrett, J Lee, J Gollihar, Y Tanno, G Delidakis, A Pothukuchy, J Ellefson, J Goronzy, JA Maynard, A Ellington, G Ippolito and G Georgiou. One step ultra-high-throughput sequencing of the paired antibody VH: VL and TCRβ: α repertoires using cell lysate resistant xenopolymerase in emulsion. The Journal of Immunology 204 (1 Supplement), 86.22-86.22. May 1, 2021.
-
H Tanno, JR McDaniel, CA Stevens, WN Voss, R Durrett, J Lee, J Gollihar, Y Tanno, G Delidakis, A Pothukuchy, JW Ellefson, JJ Goronzy, JA Maynard, AD Ellington, GC Ippolito and G Georgiou. A Facile technology for the high throughput sequencing of the paired VH:VL and TCRb:TCRa repertoires. Science Advances 6(17): eaay9093. April 22, 2020.
-
AW Nguyen, AM DiVenere, JA Papin, S Connelly, M Kaleko and JA Maynard. Neutralization of pertussis toxin by a single antibody prevents clinical pertussis in neonatal baboons. Science Advances 6 (6): eaay9258. February 5, 2020.
-
AW Nguyen, K Le and JA Maynard. Engineering Antibodies on the Surface of CHO Cells. Genotype Phenotype Coupling, 397-422. 2020.